Analysts Offer Insights on Healthcare Companies: DaVita (DVA) and Amedisys (AMED)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DaVita (DVA) and Amedisys (AMED) with bullish sentiments.
In a report issued on April 29, Pito Chickering from Deutsche Bank maintained a Buy rating on DaVita, with a price target of $150.00. The company’s shares closed last Friday at $116.53.
According to TipRanks.com, Chickering is a 4-star analyst with an average return of 19.1% and a 64.9% success rate. Chickering covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, ACADIA Pharmaceuticals, and Baxter International.
The word on The Street in general, suggests a Hold analyst consensus rating for DaVita with a $118.25 average price target.
See today’s analyst top recommended stocks >>
Deutsche Bank analyst Justin Bowers maintained a Buy rating on Amedisys on April 29 and set a price target of $340.00. The company’s shares closed last Friday at $269.85.
Bowers has an average return of 27.9% when recommending Amedisys.
According to TipRanks.com, Bowers is ranked #1393 out of 7490 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amedisys with a $334.29 average price target, a 18.0% upside from current levels. In a report issued on April 29, Oppenheimer also maintained a Buy rating on the stock with a $325.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.